Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 8von Hippel-Lindau Disease 3Pheochromocytoma 2Paraganglioma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Kidney Neoplasms 1Hemangioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Specimen Handling 5Nivolumab 5Ipilimumab 5Magnetic Resonance Spectroscopy 4CTLA-4 Antigen 4cabozantinib 3Blood Specimen Collection 2Biopsy 2fludarabine 1belzutifan 1Tissue Banks 1Pluvicto 1Inulin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Clear-cell metastatic renal cell carcinoma × belzutifan × Clear all
NCT07179770 2025-09-23

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

NYU Langone Health

Phase 1 Recruiting
12 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡